Saturday, October 3, 2026

U.S. Treasury Yields Cross 4.34%, Repricing Growth Stocks From Montreal to São Paulo

U.S. 10-year Treasury yields climbed from 3.97% to 4.34%, resetting the global risk-free rate benchmark that underpins equity valuations worldwide. High-PEG growth stocks bore immediate losses on May 12, with Canadian firm Lightspeed Commerce falling 5.58% and Brazilian-founded CI&T trailing the S&P 500 year-to-date. The 4.3% threshold has become a structural dividing line between value resilience and growth vulnerability across international markets.

LM Salvado
LM Salvado

May 13, 2026

U.S. Treasury Yields Cross 4.34%, Repricing Growth Stocks From Montreal to São Paulo
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

U.S. 10-year Treasury yields crossed 4.34% on May 12, rising from 3.97%1 — a move that resets the global discount rate embedded in every equity valuation model worldwide. Because U.S. Treasuries serve as the universal risk-free benchmark, the repricing extends far beyond American markets.

The pain concentrates in high-PEG stocks: companies priced on earnings years into the future. When the risk-free rate rises, those distant cash flows lose present value. The effect is mathematical, not regional.

The cross-border pattern was visible on May 12. Montreal-headquartered Lightspeed Commerce (LSPD) fell 5.58%1 on a day the broader market gained. São Paulo-founded CI&T has underperformed the S&P 500 year-to-date1. U.S.-based Autodesk dropped 3.45%1. No company-specific news drove any of these moves — rate pressure did.

The PEG ratio measures the premium investors pay per unit of future growth. Dick's Sporting Goods carries a PEG of 3.21; Booz Allen Hamilton sits at 4.451 — both well above industry norms. At 3.97% yields, both were defensible. At 4.34%, the math changes.

The 10-Year Constant Maturity Rate moved from 4.29% to 4.34%1, confirming sustained pressure rather than a single-day spike. European growth stocks, Asian tech firms, and emerging market software companies face identical pressure on their DCF models — the risk-free rate they are discounted against has shifted.

The market split is clean. Value stocks with near-term earnings and low PEG ratios are relatively insulated. Long-duration growth names — software, AI infrastructure — absorb each basis point rise as a direct valuation haircut.

For global investors, 4.3% functions as a structural threshold. Above it, the divergence between rate-sensitive growth stocks and the broader index accelerates. That level is now in the past.

Portfolio construction that ignores duration risk in equity positions — not just bond positions — is the central error of this rate environment. For growth-oriented holdings anywhere in the world, it has become the primary risk.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com